No benefit from adjuvant sunitinib, sorafenib in locally advanced renal cell carcinoma

the ONA take:

According to initial results presented this week at the 2015 Genitourinary Cancers Symposium in Orlando, Florida, the use of either Nexavar (sorafenib) or Sutent (sunitinib) provide no benefit to patients with locally advanced renal cell carcinoma who are at a high risk of recurrence.

The phase 3 trial conducted by the ECOG-ACRIN Cancer Research Group is the first and largest study reporting on the efficacy of sunitinib or sorafenib in patients who have undergone surgery to remove the kidney tumor.

"Unfortunately we found that the use of sunitinib or sorafenib in this setting did not reduce the incidence of recurrence as compared to standard care," said lead researcher Naomi B. Haas, MD, from the University of Pennsylvania's Abramson Cancer Center in Philadelphia.

For the international, phase III study, researchers enrolled 1,943 patients considered at high risk for recurrence following surgery to remove a kidney tumor and randomly assigned them to receive sorafenib, sunitinib, or placebo for 1 year.

Results of the study showed a median progression-free survival of 5.6 years for those treated with sunitinib compared with 5.6 years for those treated with sorafenib and 5.7 years for those who received placebo. 

Adrenalectomy Rates Remain High in Radical Nephrectomy
Use of either Nexavar (sorafenib) or Sutent (sunitinib) provide no benefit to patients with locally advanced renal cell carcinoma.
Research results highlighted today at the press conference of a major medical meeting report no benefit from the use of either Sutent (sunitinib) or Nexavar (sorafenib) among patients with locally advanced renal cell carcinoma at high risk of recurrence.
READ FULL ARTICLE From Medical Express
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs